Human Papillomavirus, Genital Warts and Vaccination

2009 ◽  
Vol 2 (9) ◽  
pp. 522-529 ◽  
Author(s):  
Laura Pye
Keyword(s):  
Human Papillomavirus ◽  
Natural History ◽  
Clinical Presentation ◽  
Hpv Vaccination ◽  
Genital Warts ◽  
Condyloma Acuminata ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
History Of ◽  
The Uk

Genital warts (condyloma acuminata) are caused by the human papillomavirus (HPV) and are the most frequently diagnosed viral sexually transmitted infection in the UK. This article aims to provide an overview of the natural history of HPV, the clinical presentation and management of genital warts and an overview of the national HPV vaccination programme.

Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis

2020 ◽  
Vol 31 (7) ◽  
pp. 606-612
Author(s):  
Husein Husein-ElAhmed
Keyword(s):  
Human Papillomavirus ◽  
Meta Analysis ◽  
Hpv Vaccination ◽  
Genital Warts ◽  
Control Group ◽  
Effect Estimate ◽  
Human Papillomavirus Vaccine ◽  
Eligibility Criteria ◽  
Transmitted Infection ◽  
Sexually Transmitted

Human papillomavirus (HPV) is the most prevalent sexually transmitted infection worldwide and ano-genital warts (AGWs) are highly infectious. This virus is transmitted through sexual, anal, or oral contact as well as skin-to-skin contacts. Treatment for this condition has significant morbidity and it can be frustrating in certain cases. The HPV vaccination has been demonstrated as a promising strategy of secondary prevention in HPV-related diseases such as head and neck cancers, cervical diseases, and recurrent respiratory papillomatosis. Regarding AGWs, it is unclear whether vaccination can provide analogous clinical benefit. The aim of this work is to systematically review the literature regarding HPV vaccination for secondary disease prevention after treatment of AGWs. From October to December 2018, a systematic search for clinical trials was conducted in five databases: PubMed, MEDLINE, EMBASE, Cochrane, and clinicaltrials.gov using a combination of the following descriptors: ‘gardasil’ OR ‘cervarix’ OR ‘nine-valent’ OR ‘9-valent’ OR ‘vaccine’ AND ‘recurrence’ OR ‘relapse’ AND ‘hpv’ OR ‘papillomavirus’ AND ‘warts’ OR ‘condyloma.’ Data were synthetized and entered in the Review Manager software (RevMan 5.3.5) to perform the meta-analysis. The search yielded 824 potentially relevant studies. Two studies fulfilled the eligibility criteria involving 656 participants. The meta-analysis estimated the rate of recurrence of AGWs was similar between the vaccine group and the control group. The overall effect estimate was 1.02 (0.75–1.38). This is the first meta-analysis exploring the effect of HPV vaccine in preventing the relapse of AGWs. These results suggest that HPV vaccination does not provide secondary benefit in patients with previous AGWs. However, these results cannot be generalized due to the scarce number of RCTs currently available in the literature. The outcomes from future randomized controlled trials (RCTs) are warranted to further clarify the precise effect of the vaccine.

Review of Evidence and Recommendation for Human Papillomavirus (HPV) Vaccination of Canadian Males Over the Age of 26 Years

2020 ◽  
Vol 24 (3) ◽  
pp. 285-291 ◽  
Author(s):  
Alex Derstenfeld ◽  
Kyle Cullingham ◽  
Zhuo Cai Ran ◽  
Ivan V. Litvinov
Keyword(s):  
Human Papillomavirus ◽  
Sexually Transmitted Infection ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Older Men ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Vaccination Programs ◽  
Sexually Transmitted ◽  
Control And Prevention

Human papillomavirus (HPV) remains the most common sexually transmitted infection with a lifetime incidence of over 75%. Based on US data from the Centers for Disease Control and Prevention (CDC), 64% of invasive HPV-associated cancers are attributable to HPV 16 or 18 (65% for females; 63% males) and may be prevented by vaccination with either the quadrivalent or nonavalent HPV vaccine. Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada. Yet, only recently have guidelines begun to consider vaccination of men older than 26 years of age. There now exist compelling reasons to recommend vaccination against HPV amongst males >26 years of age. Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.

scholarly journals Preparations for implementing human papillomavirus vaccination should begin

2005 ◽  
Vol 10 (37) ◽  
Author(s):  
M Lehtinen
Keyword(s):  
Human Papillomavirus ◽  
World Health Organization ◽  
Sexually Transmitted Infection ◽  
Hpv Vaccination ◽  
World Health ◽  
Human Papillomavirus Vaccination ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
National Programmes ◽  
Health Organization

At a World Health Organization meeting, the latest developments in human papillomavirus (HPV) vaccination were discussed. The leading theme that emerged was how to implement within national programmes the concept of vaccinating adolescents both against a common sexually transmitted infection

scholarly journals Transmission of Human Papillomavirus Without Sexual Contact

2016 ◽  
Vol 6 (1) ◽  
pp. 8-12
Author(s):  
Panteha Tavassol ◽  
Naweed Ahmed ◽  
Wakqas Kayani ◽  
Sahab Jamshidi ◽  
Suneil Bapat ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
South Asian ◽  
Viral Infections ◽  
Genital Warts ◽  
Sexual Contact ◽  
Early Age ◽  
Sexually Transmitted ◽  
Physical Environments ◽  
History Of ◽  
Males And Females

Human papillomavirus (HPV) is one of the most common sexually transmitted infections. There are four common HPV strains: 6, 11, 16, and 18. Strains 6 and 11 cause genital warts, while strains 16 and 18 are asymptomatic in males and may progress to cervical cancer in females. Although uncommon, a small percentage of males and females have been diagnosed with HPV without previous sexual contact. In this case report, we discuss a case conducted on a 15-year-old South Asian male who contracted an unknown low-risk strain of HPV with no history of sexual contact. HPV is highly infectious, however in the majority of cases the immune system is able to clear the infection, preventing the appearance of genital warts. In cases such as these, it is important to help control the spread of viral infections. Several determinants of health are involved in and affect the transmission of HPV, including income and social status, social support networks, education and literacy, culture, social and physical environments, and health services. To aid in the prevention of HPV, sexual education should be taught at early ages within schools and the Gardasil® vaccine should be administered to both females and males at an early age to reduce the burden of disease and the incidence of HPV.

Human Papillomavirus Infection and Prevention In The Adolescent

2020 ◽  
Author(s):  
Alexandria Richards ◽  
Joanna Stacey
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Transmitted Disease ◽  
Cervical Dysplasia ◽  
Vaccine Safety ◽  
Genital Warts ◽  
Hpv Infection ◽  
Sexually Transmitted ◽  
Papillomavirus Infection

Human papillomavirus, or HPV, is a common sexually transmitted disease, most often acquired during the adolescence or the early 20s. It can be divided into oncogenic and nononcogenic serotypes. It is responsible for genital warts as well as pathologic diseases that can lead to genital cancers and cancers of the oropharyngeal tract in both males and females. The majority of adolescents who acquire HPV infections do not go on to develop cancer. New discoveries about the virus’ persistence and latency direct how we treat adolescents with HPV infections. Recommendations for prevention of HPV include use of the 9-valent vaccine against the most common oncogenic HPV serotypes. Screening should be delayed until the age of 21, with the exception of immunocompromised women. The HPV vaccination is safe and effective, and does not encourage sexual activity among adolescents. Both boys and girls should be vaccinated against HPV at 11 to 12 years of age but may receive the vaccination as early as 9 or as late as 21 (males) or 26 (females) years of age. The vaccine may now also be given in only two doses if the series was started before the age of 15. Follow-up studies in the years after the vaccine’s introduction have shown large decreases in HPV infection rates. This review contains 7 figures, 7 tables and 63 references Key Words: Oncogenic subtype, Oropharyngeal cancer, Infection persistence, Immune tolerance, Cervical dysplasia, Genital warts, 9-valent vaccine, Vaccine safety  

Domestic violence in a genitourinary medicine setting – an anonymous prevalence study in women

2008 ◽  
Vol 19 (11) ◽  
pp. 747-751 ◽  
Author(s):  
W C Loke ◽  
L Bacchus ◽  
C Torres ◽  
E Fox
Keyword(s):  
Domestic Violence ◽  
Partner Violence ◽  
Illicit Drugs ◽  
Cross Sectional Survey ◽  
Transmitted Infection ◽  
Cross Sectional ◽  
Sexually Transmitted ◽  
Medicine Clinic ◽  
History Of ◽  
The Uk

Domestic violence (DV) affects around one in four women in the UK. This study aimed to determine the prevalence of DV and the associations with sociodemographic and sexual behaviour variables in female attendees of an inner-city genitourinary (GU) medicine clinic. In this cross-sectional survey, 177 of 380 women (46.6%) disclosed a history of abuse and 17.4% reported DV in the preceding 12 months. Women with a history of a sexually transmitted infection (STI) were more likely to have experienced DV at some point in their lives (odds ratio [OR] = 2.39; 95% confidence interval [CI]: 1.58–3.63). Logistic regression analysis revealed that being black compared with white, (OR = 1.7; 95% CI: 2.4–12.5) current cohabitation with a partner (OR = 2.24; 95% CI: 1.06–4.75), increasing number of sexual partners in the last year (OR = 1.24; 95% CI: 1.01–1.5) and consumption of illicit drugs (OR = 2.05; 95% CI: 1.02–4.11) were significantly associated with DV in the last 12 months but age, current occupation, history of STIs, age of coitarche and condom use were not. DV was common in this GU medicine clinic population and associated with STIs. We recommend that health practitioners undergo training to increase awareness of the links between partner violence and sexual health problems.

scholarly journals Profil Penderita Kondiloma Akuminata Di Poliklinik Kulit Dan Kelamin Rumah Sakit Pertamina Bintang Amin Periode Januari 2016 Sampai Desember 2019

2021 ◽  
Vol 1 (3) ◽  
pp. 237-246
Author(s):  
Arif Effendi ◽  
Ratna Purwaningrum ◽  
Muhammad Syafei Hamzah ◽  
Aland Maulana
Keyword(s):  
Human Papillomavirus ◽  
Sexually Transmitted Infections ◽  
Sexually Transmitted Infection ◽  
Health Workers ◽  
Descriptive Analysis ◽  
Early Adulthood ◽  
Health Condition ◽  
Condyloma Acuminata ◽  
Transmitted Infection ◽  
Sexually Transmitted

ABSTRACT: PROFILE OF CONDYLOMA AKUMINATA PATIENTS IN THE SKIN AND SEX POLYCLINIC OF PERTAMINA BINTANG AMIN HOSPITAL FOR THE PERIOD OF JANUARY 2016 TO DECEMBER 2019. Introduction: Sexually transmitted infection (STI) is one of the diseases and causes of health, social and economic problems in many countries. According to WHO, more than 1 million sexually transmitted infections are acquired every day in various parts of the world and more than 290 million women have human papillomavirus infection. In America, data from the CDC shows new cases with more than 19.7 million sexually transmitted infections each year, and about 14.1 million cases are human papillomavirus infections. Objective: This study aims to find out information about the profile of condyloma acuminata sufferers at the Dermatology and Venereology Polyclinic at Pertamina Bintang Amin Hospital for the period January 2016 to December 2019.Methods: This study used quantitative descriptive analysis with the aim of knowing the profile of patients with condyloma acuminata. Sampling was done by using the total sampling method. The sample in this study were patients with condyloma acuminata who were treated at the Dermatology and Venereology Polyclinic at Pertamina Bintang Amin Hospital for the period January 2016 to December 2019 totaling 22 patient medical records. Results: It was found that patients with condyloma acuminata were more commonly found in the age group of 26 to 35 years (early adulthood), as many as 9 patients (40.9) in the female sex, namely 17 patients (77.3%) with married status. as many as 17 patients (77.3) while based on the management of patients more were given treatment using electric surgery, namely as many as 8 patients (36.4%).Conclusion: Patients with condyloma acuminata in order to maintain their health condition, and avoid risk factors that can increase the occurrence of condyloma acuminata, it is hoped that health workers can hold health promotion activities about the prevention of sexually transmitted diseases, especially condyloma acuminata and this research can be used as additional information to develop further research regarding the factors that have not been studied in this study Keywords: Condyloma acuminata, sexually transmitted infection, HPV

Anal and oral human papillomavirus infection in men who have sex with men: implications for risk-targeted vaccination

2020 ◽  
Vol 15 (18) ◽  
pp. 1713-1722
Author(s):  
Maria Gabriella Donà ◽  
Francesca Rollo ◽  
Alessandra Latini ◽  
Maria Benevolo ◽  
Barbara Pichi ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Linear Array ◽  
Hpv Vaccination ◽  
Risk Groups ◽  
Sexually Active ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Papillomavirus Infection ◽  
Significant Burden ◽  
Sex With Men

Aim: Men who have sex with men (MSM) harbor a significant burden of human papillomavirus (HPV)-related diseases that could be prevented by vaccination. Materials & methods: Prevalence of HPVs targeted by the quadrivalent (4vHPV) and nonavalent vaccines (9vHPV) was assessed in anal (n = 443) and oral (n = 193) specimens of immunocompetent, sexually active MSM, using the Linear Array. Results: Of the anal samples, 34.1 and 46.0% were positive for at least one genotype of those covered by the 4vHPV and 9vHPV, respectively. At least one of the HPVs targeted by the 9vHPV was detected in 5.7% of the oral specimens. Conclusion: The majority of the subjects were not currently infected by HPV-16 and other vaccine-preventable HPVs. Universal HPV vaccination should be strongly promoted in order to achieve protection for all risk groups. In the meanwhile, vaccination should be offered to sexually active adult MSM attendees of sexually transmitted infection centers, although its potential benefit for these subjects needs to be further investigated.

scholarly journals Surgical Management of Giant Genital Condyloma Acuminata by Using Double Keystone Flaps

2016 ◽  
Vol 2016 ◽  
pp. 1-5
Author(s):  
Peri Eriad Yunir ◽  
Chaidir A. Mochtar ◽  
Agus Rizal A. H. Hamid ◽  
Chaula L. Sukasah ◽  
Rainy Umbas
Keyword(s):  
Human Papillomavirus ◽  
Sexually Transmitted Disease ◽  
Transmitted Disease ◽  
External Genitalia ◽  
Surgical Excision ◽  
Genital Warts ◽  
Condyloma Acuminata ◽  
Split Thickness Skin Graft ◽  
Sexually Transmitted ◽  
Thickness Skin

Condyloma acuminata in the external genitalia (genital warts) is a sexually transmitted disease that is often caused by human papillomavirus (HPV). We report a case of giant genital condyloma acuminata in a 35-year-old male patient with HIV comorbidity treated by wide surgical excision. Excision defect was covered with split thickness skin graft (STSG) and double keystone flaps. There was no complication after surgery. Ten months following surgery, there was no new condyloma lesion and the patient had normal voiding and erectile functions.

Sign in / Sign up

Export Citation Format

Share Document